Simply Wall St.155d agoneutral
A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For AmtagviNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
104last 24h
3124last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Insider Monkey156d agobullish
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now?Insider Monkey157d agobullish
Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15%Simply Wall St.160d agoneutral
Does FDA Clearance for IOV-5001 TIL-IL12 Trial Change The Bull Case For Iovance Biotherapeutics (IOVA)?Simply Wall St.169d agoneutral
Assessing Iovance Biotherapeutics (IOVA) Valuation After Strong Recent Share Price MomentumSimply Wall St.183d agobullish
Why Iovance Biotherapeutics (IOVA) Is Up 5.7% After AMTAGVI-Driven Q1 Revenue Jump And Share PlanSimply Wall St.186d agoneutral
A Look At Iovance Biotherapeutics (IOVA) Valuation As Short Interest Eases And Institutions Add ExposureMotley Fool190d agobullish
This Beaten-Down Growth Stock Could Soar 165%, According to Wall StreetSimply Wall St.193d agoneutral
Iovance Share Increase Proposal Weighs Dilution Risk Against TIL Growth Funding